Symbiox Investment & Trading Co. Ltd. has intimated stock exchanges of a forthcoming Board of Directors meeting, scheduled for Saturday, May 23, 2026, at 1:30 P.M. at the company's registered office in Kolkata. The notice, dated May 14, 2026, has been filed pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and has been communicated to the Metropolitan Stock Exchange of India Limited, The Calcutta Stock Exchange Limited, and The Bombay Stock Exchange Limited.

Board Meeting Agenda

The board meeting has been convened to transact several key matters. The following agenda items are scheduled for consideration:

Key Regulatory Context

The approval of financial results will be carried out under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs the disclosure of financial results by listed entities. The board will consider both the audited financial results and the associated limited review report for the quarter and full year ended March 31, 2026.

Auditor Appointments for FY 2026-27

Among the notable agenda items are two auditor appointments for the upcoming financial year. The board will consider appointing Mr. Akhil Agarwal, Practising Company Secretary, as Secretarial Auditor of the company for FY 2026-27. Additionally, the appointment of Mrs. Shikha Singhal, Chartered Accountant, as Internal Auditor for FY 2026-27 will also be deliberated upon.

The intimation was signed by Khushboo Pitti, Company Secretary and Compliance Officer (M. No. A25950), on behalf of Symbiox Investment & Trading Co. Ltd.

Symbiox Investment & Trading Co Ltd has announced its unaudited financial results for the third quarter of fiscal year 2026, following the board meeting held on February 7, 2026. The company reported revenue from operations of ₹8.60 lakh and net profit of ₹1.23 lakh for the quarter ended December 31, 2025.

Board Meeting Outcome and Approval

The board meeting was successfully conducted on Saturday, February 7, 2026, at the company's registered office in Kolkata, commencing at 2:30 P.M. and concluding at 3:20 P.M. The directors approved the unaudited financial results pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, along with the Auditor's Limited Review Report.

Q3FY26 Financial Performance

The company's financial performance for the quarter ended December 31, 2025, showed mixed results compared to previous periods. Revenue from operations declined significantly to ₹8.60 lakh from ₹23.15 lakh in the previous quarter and ₹45.47 lakh in the corresponding quarter of the previous year.

Nine-Month Performance Analysis

For the nine months ended December 31, 2025, the company reported total income of ₹77.79 lakh compared to ₹151.90 lakh in the corresponding period of the previous year. Net profit for the nine-month period stood at ₹14.01 lakh, significantly lower than ₹49.13 lakh achieved in the previous year.

Regulatory Compliance and Auditor Review

The financial results were reviewed by the Audit Committee and received a clean auditor's report from S S R V & Associates, Chartered Accountants. The independent auditors confirmed that the unaudited financial results comply with applicable accounting standards and SEBI regulations, with no material misstatements identified.

Stock Exchange Notifications

Symbiox Investment & Trading Co Ltd has formally notified all relevant stock exchanges about the board meeting outcome and financial results. The company maintains listings on multiple exchanges with trading symbols BSE: 539278, CSE: 029461, and MSE: SYMBIOX. The notifications were signed by Khushboo Pitti, Company Secretary and Compliance Officer, ensuring full regulatory compliance.